Vol 17, No 2 (2021)
Review paper
Published online: 2021-03-26

open access

Page views 545
Article views/downloads 532
Get Citation

Connect on Social Media

Connect on Social Media

Quality of life of patients with advanced pancreatic cancer

Ireneusz Raczyński1, Barbara Radecka23
Oncol Clin Pract 2021;17(2):74-80.


Pancreatic cancer is one of the most common malignancies with poor prognosis and high mortality. Advanced-stage disease at diagnosis and the dominant clinical symptoms significantly deteriorate the quality of life. The paper presents an analysis of the results of quality of life studies in patients with locally advanced and metastatic pancreatic cancer, as well as the relationship between therapeutic decisions and quality of life indicators. It has been shown that the initial assessment of life quality can have prognostic value. Appropriate symptomatic treatment of patients with advanced pancreatic cancer improves the quality of life, increases the compliance and prolongs survival. The assessment of the quality of life in patients with advanced pancreatic cancer has multivariable significance, which is not limited only to improving the quality of life.

Article available in PDF format

View PDF Download PDF file


  1. Yalcin S, Dane F, Oksuzoglu B, et al. Quality of life study in patients with unresectable locally advanced or metastatic pancreatic cancer treated with gemcitabine in combination with nab-paclitaxel versus gemcitabine alone:ax-panc-sy001: A phase II randomized study. J Clin Oncol. 2018; 36(4_suppl): 346–346.
  2. Kristensen A, Vagnildhaug OM, Grønberg BH, et al. Does chemotherapy improve health-related quality of life in advanced pancreatic cancer? A systematic review. Crit Rev Oncol Hematol. 2016; 99: 286–298.
  3. Scheithauer W, Ramanathan RK, Moore M, et al. Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial. J Gastrointest Oncol. 2016; 7(3): 469–478.
  4. Carrato A, Falcone A, Ducreux M, et al. A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs. J Gastrointest Cancer. 2015; 46(3): 201–211.
  5. Mackay TM, Smits FJ, Latenstein AEJ, et al. Dutch Pancreatic Cancer Group. Impact of nationwide enhanced implementation of best practices in pancreatic cancer care (PACAP-1): a multicenter stepped-wedge cluster randomized controlled trial. Trials. 2020; 21(1): 334–351.
  6. Didkowska J, Wojciechowska U, Czaderny K, et al. Nowotwory złośliwe w Polsce w 2017r. Krajowy Rejestr Nowotworów. MZ 2019 http://onkologia.org.pl/wp-content/uploads/Nowotwory_2017.pdf (Dostęp 10.05.2020).
  7. Kamisawa T, Wood L, Itoi T, et al. Pancreatic cancer. The Lancet. 2016; 388(10039): 73–85.
  8. Wolfgang CL, Herman JM, Laheru DA, et al. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013; 63(5): 318–348.
  9. Müller-Nordhorn J, Roll S, Böhmig M, et al. Health-related quality of life in patients with pancreatic cancer. Digestion. 2006; 74(2): 118–125.
  10. Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol. 2013; 31(1): 23–29.
  11. NCI SEER Cancer statistics. http://seer.cancer.gov/statfacts/html/pancreas.html (Dostęp 10.05.2020).
  12. McGuigan A, Kelly P, Turkington RC, et al. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018; 24(43): 4846–4861.
  13. Yalcin S, Dane F, Oksuzoglu B, et al. Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study. BMC Cancer. 2020; 20(1): 259–265.
  14. Juniper EF, Guyatt GH, Feeny DH, et al. Measuring health-related quality of life. Ann Intern Med. 1993; 118(8): 622–629.
  15. Felce D, Perry J. Quality of life: its definition and measurement. Res Dev Disabil. 1995; 16(1): 51–74.
  16. Bauer MR, Bright EE, MacDonald JJ, et al. Quality of life in patients with pancreatic cancer and their caregivers: a systematic review. Pancreas. 2018; 47(4): 368–375.
  17. Meyza J. Grupa studiująca jakość życia EORTC. W: de Walden-Gałuszko K, Majkowicz M (red.). Jakość życia w chorobie nowotworowej. Wyd. Uniwersytetu Gdańskiego, Gdańsk. 1994: 85–88.
  18. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85(5): 365–376.
  19. Quinten C, Coens C, Mauer M, et al. EORTC Clinical Groups. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol. 2009; 10(9): 865–871.
  20. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001; 33(5): 337–343.
  21. Ellis LM, Bernstein DS, Voest EE, et al. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol. 2014; 32(12): 1277–1280.
  22. Cheng S, McDonald EJ, Cheung MC, et al. Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the Same Construct of Clinical Benefit? J Clin Oncol. 2017; 35(24): 2764–2771.
  23. Ahlgren J. Chemotherapy for pancreatic carcinoma. Cancer. 1996; 78(3): 654–663, doi: 10.1002/(sici)1097-0142(19960801)78:3<654::aid-cncr46>3.0.co;2-v.
  24. Pasetto LM, Jirillo A, Stefani M, et al. Old and new drugs in systemic therapy of pancreatic cancer. Crit Rev Oncol Hematol. 2004; 49(2): 135–151.
  25. Burris HA. Recent updates on the role of chemotherapy in pancreatic cancer. Semin Oncol. 2005; 32(4 Suppl 6): S1–S3.
  26. Conroy T, Desseigne F, Ychou M, et al. Groupe Tumeurs Digestives of Unicancer, PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364(19): 1817–1825.
  27. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369(18): 1691–1703.
  28. Moore MJ, Hamm J, Dancey J, et al. National Cancer Institute of Canada Clinical Trials Group. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003; 21(17): 3296–3302.
  29. Bramhall SR, Schulz J, Nemunaitis J, et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer. 2002; 87(2): 161–167.